Catalyst
Slingshot members are tracking this event:
Immunomedics (IMMU) Expects to Complete Patient Enrollment in 2016 for Phase 3 Trial Evaluating Y-clivatuzumab Tetraxetan in Pancreatic Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| IMMU |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 14, 2016
Occurred Source:
http://www.immunomedics.com/pdfs/news/2016/pr03142016.pdf
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3 Trial, Y-clivatuzumab Tetraxetan, 2016, Pancreatic Cancer, Patient Enrollment
